+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hyperplasia Treatment Market by Treatment Type (Medications, Minimally Invasive Therapies, Surgical Treatments), Product Type (Catheters, Electrodes, Implants), End User - Global Forecast 2025-2030- Product Image
Benign Prostatic Hyperplasia Treatment Market by Treatment Type (Medications, Minimally Invasive Therapies, Surgical Treatments), Product Type (Catheters, Electrodes, Implants), End User - Global Forecast 2025-2030- Product Image
Sale

Benign Prostatic Hyperplasia Treatment Market by Treatment Type (Medications, Minimally Invasive Therapies, Surgical Treatments), Product Type (Catheters, Electrodes, Implants), End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 4989822
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Benign Prostatic Hyperplasia Treatment Market grew from USD 1.42 billion in 2024 to USD 1.50 billion in 2025. It is expected to continue growing at a CAGR of 5.91%, reaching USD 2.01 billion by 2030.

Benign Prostatic Hyperplasia (BPH) has drawn significant attention from the medical community and industry stakeholders alike due to its widespread prevalence and the profound effect it has on quality of life. Over the past few decades, innovation in treatment and technology has transformed the management of this condition, providing patients with a broader range of options and clinicians with new avenues for care. Advances in pharmaceutical formulations, minimally invasive procedures, and surgical techniques have all contributed to improved outcomes and a more patient-centric approach.

The market has evolved from a singular approach to a multidimensional framework, and today, it demands an in-depth analysis that encompasses various therapeutic categories, product advancements, and regional shifts. This comprehensive analysis not only outlines the current state of BPH treatment but also highlights emerging trends that promise long-term benefits for patients and healthcare providers. By delving into the shifting treatment paradigms, segmentation strategies, and varied regional performances, this executive summary sets the stage for a deeper discussion on the transformative nature of the BPH treatment landscape.

Transformative Shifts in the BPH Treatment Landscape

Recent years have witnessed seismic shifts in the methodologies used to treat BPH. The transition from traditional surgical debulking to a more refined approach that includes a combination of medications, minimally invasive procedures, and innovative surgical techniques represents a significant milestone. The industry is shifting towards precision medicine, where treatments are tailored to individual patient profiles to maximize effectiveness and minimize adverse effects.

Technology continues to be a critical enabler, with breakthrough advancements in imaging, robotics, and laser technology reshaping standard practices. Surgeons are now able to operate with increased accuracy and reduced recovery times, while new pharmacological therapies are addressing long-term management more efficiently. Moreover, clinical outcomes have improved markedly as the treatment spectrum has opened up to include methods like water vapour therapy and prostate artery embolization, which offer viable alternatives to conventional therapies. This dynamic evolution calls for a multi-faceted strategy that leverages the strengths of each treatment modality to provide patients with the most effective and personalized solutions available today.

Key Segmentation Insights in the BPH Treatment Market

The comprehensive segmentation of the BPH treatment market reveals a nuanced landscape that illustrates both the diversity and specificity of therapeutic and product solutions available. Analyzing the market on the basis of treatment type underscores three prominent categories: medications, minimally invasive therapies, and surgical treatments. Within the medications segment, there is a focused exploration of agents such as 5-Alpha-Reductase Inhibitors and Alpha Blockers, each offering distinct mechanisms of action and patient benefits. As clinicians increasingly favor less invasive methods, the spotlight has shifted towards minimally invasive therapies, where procedures like prostate artery embolization and water vapour therapy are gaining steady traction. Additionally, surgical treatments continue to uphold their critical role with techniques including laser surgery, prostatic urethral lift, transurethral incision of the prostate, and transurethral resection of the prostate.

Further analysis based on product type segments the market into a variety of innovation-driven interventions such as catheters, electrodes, implants, prostatic stents, resectoscopes, and urology laser systems. When considering the end user, the market demonstrates diversified demand patterns that reflect the varied settings of ambulatory surgical centers, specialized clinics, and large hospitals. These deep segmentation insights not only highlight distinct patient care pathways but also shed light on the investment and technological trends driving each subsegment, thereby offering a comprehensive view of market dynamics.

Based on Treatment Type, market is studied across Medications, Minimally Invasive Therapies, and Surgical Treatments. The Medications is further studied across 5-Alpha-Reductase Inhibitors and Alpha Blockers. The Minimally Invasive Therapies is further studied across Prostate Artery Embolization and Water Vapour Therapy. The Surgical Treatments is further studied across Laser Surgery, Prostatic Urethral Lift, Transurethral Incision Of The Prostate, and Transurethral Resection Of The Prostate.

Based on Product Type, market is studied across Catheters, Electrodes, Implants, Prostatic Stents, Resectoscopes, and Urology Laser.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.

Key Regional Insights Across Global Markets

Globally, the BPH treatment market exhibits a rich tapestry of regional variations that underscore the distinct healthcare environments across different geographies. In the Americas, a robust adoption of innovative techniques and an emphasis on personalized healthcare have bolstered the early adoption of advanced treatments, positioning the region as a forerunner in integrating novel technologies and patient management strategies.

Similarly, the Europe, Middle East & Africa region exhibits a confluence of high regulatory standards and a focus on cost-effectiveness that has driven a balanced mix of both traditional and state-of-the-art treatment approaches. Investment in research and clinical trials in these locales has led to an increase in the availability of cutting-edge minimally invasive therapies and surgical options that are both effective and economically viable.

In the Asia-Pacific region, rapid urbanization and an increasing focus on healthcare infrastructure have amplified the shift towards modern treatment modalities. Healthcare reforms and a growing middle-class population are fostering an environment ripe for the adoption of advanced techniques, while the region’s strong emphasis on technology-driven healthcare solutions is setting the stage for a significant transformation in BPH management.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights Driving Innovation and Growth

The competitive landscape within the BPH treatment market is characterized by a multitude of industry leaders who are driving progress through continuous innovation and strategic investments. Prominent players such as Abbott Laboratories, AbbVie Inc., and Asahi Kasei Corporation have been instrumental in shaping the ecosystem through pioneering breakthroughs. Other key entities including Astellas Pharma Inc., Bayer AG, and Boehringer Ingelheim GmbH further contribute by aligning their product pipelines with emerging market demands to enhance patient outcomes.

Additionally, companies like Boston Scientific Corporation and Cipla Ltd. have introduced state-of-the-art devices and treatment options, while firms such as Dr. Reddy’s Laboratories and Eli Lilly and Company are investing substantially in clinical research to develop more effective medications. Meanwhile, Endo International PLC, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, and Lumenis Ltd. have carved out niches by focusing on both the development of medical devices and the refining of existing therapies. Leading global players including Lupin Pharmaceuticals, Medtronic PLC, Merck & Co., Inc., Merit Medical Systems, Mylan N.V., Olympus Corporation, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd. continue to push the boundaries by leveraging robust R&D capabilities and strategic partnerships. Each of these companies contributes to a vibrant competitive environment that fuels innovation, ensures quality improvements, and ultimately leads to enhanced patient care across the board.

The report delves into recent significant developments in the Benign Prostatic Hyperplasia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Cipla Ltd., Dr. Reddy’s Laboratories, Eli Lilly and Company, Endo International PLC, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lumenis Ltd., Lupin Pharmaceuticals, Medtronic PLC, Merck & Co., Inc., Merit Medical Systems, Mylan N.V., Olympus Corporation, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd..

Actionable Recommendations for Industry Leaders

Given the dynamic and multifaceted nature of BPH treatment, industry leaders are well advised to adopt forward-thinking strategies that align with the transformative trends shaping the market. First, it is crucial to invest in research and development initiatives that not only refine current treatment modalities but also explore novel therapeutic options. By embracing innovation in both pharmaceuticals and technology-driven therapies, companies can position themselves at the forefront of this competitive landscape.

Another critical recommendation is to enhance collaborations with key clinicians, research institutions, and regulatory bodies across multiple regions. Such alliances can facilitate the early adoption of breakthrough treatments and enable comprehensive clinical trials that validate new techniques. By developing robust partnerships across diverse end-user settings - ranging from ambulatory surgical centers to large hospitals - industry players can harmonize their product offerings with real-world patient needs.

Furthermore, an emphasis on regional market trends and tailored human-centric approaches will be key for capturing a wider audience. For example, leveraging digital platforms to disseminate critical product information and treatment efficacy can help reach different demographics more effectively. Lastly, companies should continuously monitor competitive movements and regional regulatory changes. Adopting adaptive strategies that incorporate emerging trends and evolving market demands will be essential for maintaining a competitive edge. This proactive approach is instrumental in ensuring sustainable growth and delivering cost-effective, innovative solutions to a diverse patient base.

Embracing a Future of Medical Innovation in BPH Treatment

In conclusion, the landscape of BPH treatment has undergone significant transformation, driven by innovative breakthroughs in pharmacological therapies, minimally invasive procedures, and diverse surgical techniques. The industry has witnessed powerful shifts - from a one-dimensional approach to a nuanced paradigm characterized by detailed segmentation across treatment and product types and varying end user demands. Global market dynamics further enrich this landscape, with differentiated regional insights underscoring the varying pace of adoption and technological integration.

Moreover, the competitive environment is marked by the presence of multiple leading companies that continuously refine their strategies to meet the emerging needs of patients and healthcare providers. By focusing on research, strategic alliances, and patient-centric innovations, the industry is forging a path that promises to enhance outcomes and drive unparalleled advancements in patient care. The insights provided herein offer a strong foundation for understanding the current state of the market and the future direction of BPH treatment. Ultimately, the melding of technology, innovation, and personalized care is set to redefine standards and improve the quality of life for millions of patients globally.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence and improved diagnosis of benign prostatic hyperplasia conditions
5.1.1.2. Growing patient awareness and preference for effective non-surgical treatment options
5.1.1.3. Expansion of healthcare infrastructure globally
5.1.2. Restraints
5.1.2.1. Lack of awareness about benign prostatic hyperplasia symptoms
5.1.3. Opportunities
5.1.3.1. Ongoing innovations in minimally invasive treatments for benign prostatic hyperplasia
5.1.3.2. Leveraging big data analytics to enhance benign prostatic hyperplasia diagnostic and treatment processes
5.1.4. Challenges
5.1.4.1. Regulatory complexities for benign prostatic hyperplasia treatments
5.2. Market Segmentation Analysis
5.2.1. Treatment Type: Growing preference for benign prostatic hyperplasia treatment using medication and surgical treatment
5.2.2. End User: Increasing use of benign prostatic hyperplasia treatment in ambulatory surgical centers
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type
6.1. Introduction
6.2. Medications
6.2.1. 5-Alpha-Reductase Inhibitors
6.2.2. Alpha Blockers
6.3. Minimally Invasive Therapies
6.3.1. Prostate Artery Embolization
6.3.2. Water Vapour Therapy
6.4. Surgical Treatments
6.4.1. Laser Surgery
6.4.2. Prostatic Urethral Lift
6.4.3. Transurethral Incision Of The Prostate
6.4.4. Transurethral Resection Of The Prostate
7. Benign Prostatic Hyperplasia Treatment Market, by Product Type
7.1. Introduction
7.2. Catheters
7.3. Electrodes
7.4. Implants
7.5. Prostatic Stents
7.6. Resectoscopes
7.7. Urology Laser
8. Benign Prostatic Hyperplasia Treatment Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Clinics
8.4. Hospitals
9. Americas Benign Prostatic Hyperplasia Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2024
12.2. FPNV Positioning Matrix, 2024
12.3. Competitive Scenario Analysis
12.3.1. Mount Sinai launches a new robotic system for treating an enlarged prostate.
12.3.2. Zenflow secures USD 24 million Series C to drive FDA pre-market approval and commercialization of Spring System
12.3.3. Rivermark Medical secures USD 30 million Series C investment for development of FloStent
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 15. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 17. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 23. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 54. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 55. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 56. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 86. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 87. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 88. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 92. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 94. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 104. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 140. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 165. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 195. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 196. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 197. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 219. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 220. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 221. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 225. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 226. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 227. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 267. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lumenis Ltd.
  • Lupin Pharmaceuticals
  • Medtronic PLC
  • Merck & Co., Inc.
  • Merit Medical Systems
  • Mylan N.V.
  • Olympus Corporation
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.5 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.01 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Benign Prostatic Hyperplasia (BPH) Treatment Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Benign Prostatic Hyperplasia (BPH) Treatment Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 151 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Devices Market - Product Image

Benign Prostatic Hyperplasia Treatment Devices Market

  • Report
  • 200 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 96 Pages
  • Global
From
Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 97 Pages
  • Global
From

About the Benign Prostatic Hyperplasia Drug Market

Benign Prostatic Hyperplasia (BPH) is a condition that affects the prostate gland in men. It is characterized by an enlarged prostate, which can cause urinary symptoms such as difficulty starting or stopping the flow of urine, a weak or interrupted urine stream, and a feeling of incomplete bladder emptying. BPH is not cancerous, but it can lead to an increased risk of developing prostate cancer. The BPH drug market is composed of a variety of medications used to treat the symptoms of BPH. These medications include alpha-blockers, 5-alpha reductase inhibitors, and anticholinergics. Alpha-blockers work by relaxing the muscles of the bladder neck and prostate, allowing for improved urine flow. 5-alpha reductase inhibitors reduce the size of the prostate, while anticholinergics reduce bladder contractions. The BPH drug market is a subset of the larger prostate cancer drug market. Prostate cancer drugs are used to treat prostate cancer, which is the second most common cancer in men. These drugs include hormone therapy, chemotherapy, and immunotherapy. Some companies in the BPH drug market include Allergan, Astellas Pharma, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.